NCT01668654View on ClinicalTrials.gov

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

PHASE3TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 4, 2012

Primary Completion Date

June 18, 2013

Study Completion Date

June 18, 2013

Conditions
Epilepsy
Interventions
DRUG

retigabine/ezogabine

retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight

Trial Locations (4)

33414

GSK Investigational Site, Wellington

38105

GSK Investigational Site, Memphis

90027

GSK Investigational Site, Los Angeles

75230-2507

GSK Investigational Site, Dallas

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS | Biotech Hunter | Biotech Hunter